Board Appointment Signals Strategic Backing
As part of the investment, Mario Barro, head of infectious diseases at RA Capital Management, will join ILiAD’s board of directors.
Barro described BPZE1 as a promising opportunity to confront the enduring burden of pertussis. Across six clinical studies, he said, the candidate has shown potential to significantly advance prevention efforts.
He highlighted the vaccine’s needle-free delivery and its ability to generate strong mucosal immunity, which he said may provide a more durable immune response capable of blocking both disease and transmission.
Looking Ahead
With fresh capital in hand, ILiAD now moves into its next phase — navigating the complexities of human challenge trials and the long regulatory road beyond. For a disease that has lingered like a shadow despite decades of vaccines, the company’s progress could signal a turning point.
Information regarding legal counsel advising ILiAD on the financing was not immediately available Tuesday.
